Phase 1/2 Study Of Pf-03084014 In Combination With Gemcitabine And Nab-paclitaxel In Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma
Phase of Trial: Phase I/II
Latest Information Update: 17 Jan 2019
Price : $35 *
At a glance
- Drugs Nirogacestat (Primary) ; Gemcitabine; Paclitaxel
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pfizer
- 31 Aug 2018 Biomarkers information updated
- 16 Jul 2015 Planned End Date changed from 1 Apr 2019 to 1 Nov 2015 as reported by ClinicalTrials.gov record.
- 16 Jul 2015 Planned primary completion date changed from 1 Apr 2019 to 1 Nov 2015 as reported by ClinicalTrials.gov record.